ACLX

NEUTRALM&A

Arcellx, Inc.

2026-04-22

Price

$115.00

+0.02%

Score14.5Top Tier

Signals5/8 DNA2/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.9xvs 20d avg

Analysis

Arcellx's (ACLX) price action is entirely anchored by High-Conviction Price Discovery following Gilead Sciences' definitive agreement to acquire the company for $115 per share in cash plus a $5 Contingent Value Right (CVR). The exceptionally low realized volatility (1.1%) and the presence of technical signals like QUIET_STORM and STEADY_CLIMB are textbook mechanical reflections of merger arbitrage, with the stock pinning exactly to the $115 upfront buyout price. While the current RISK_ON macro regime and abundant market liquidity provide a frictionless backdrop for M&A activity, ACLX's idiosyncratic catalyst overrides broader market beta, shifting the focus strictly to the deal's expected Q2 2026 closure and the future CVR payout.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKQUIET ACCUMULATIONSELLER FATIGUE

Key Takeaways

ACLX is trading as a pure merger arbitrage play following Gilead's $7.8 billion buyout agreement at $115/share upfront plus a $5 CVR based on anito-cel sales [1.6].
Technical signals indicating low volatility and a steady climb are the mechanical result of the stock pegging to the acquisition price, completely decoupling it from organic market momentum.
The primary risk is regulatory or tender offer hurdles delaying the expected Q2 2026 close, while the $5 CVR offers the only remaining residual upside for long-term holders.

← Back to 2026-04-22 View Full ACLX History →Yahoo Finance &nearr;